Christina Klink
Family · Farmington, PANPI 1407289358
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 704 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 704 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$1K
- Novo Nordisk$1K
- GSK$1K
- Lilly USA, LLC$869
- Boehringer Ingelheim$638
- plus $4K from 31 others
What the payments were for
- Food & beverage$10,40599%
- Education$971%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 144 | $1,460 |
| AstraZeneca | 62 | $1,373 |
| Novo Nordisk | 91 | $1,292 |
| GSK | 70 | $1,040 |
| Lilly USA, LLC | 59 | $869 |
| Boehringer Ingelheim | 41 | $638 |
| Pfizer | 25 | $466 |
| Johnson & Johnson | 32 | $451 |
| Amgen | 24 | $416 |
| Bayer | 26 | $411 |
| Abbott | 14 | $240 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $229 |
| Exact Sciences | 11 | $203 |
| Otsuka America Pharmaceutical, Inc. | 10 | $175 |
| Astellas Pharma US Inc | 5 | $146 |
| E.r. Squibb & Sons, L.L.C. | 7 | $107 |
| Amarin Pharma, Inc. | 5 | $90 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $85 |
| Novartis | 6 | $81 |
| Eisai Inc. | 5 | $73 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $62 |
| Arbor Pharmaceuticals, Inc. | 4 | $52 |
| Sanofi Pasteur Inc. | 4 | $52 |
| Sunovion Pharmaceuticals Inc. | 4 | $49 |
| Redhill Biopharma Inc. | 3 | $48 |
| Currax Pharmaceuticals LLC | 3 | $47 |
| Neurocrine Biosciences, Inc. | 3 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Averitas Pharma Inc. | 2 | $43 |
| Merck | 3 | $40 |
| Sanofi-aventis U.S. LLC | 3 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Biodelivery Sciences International, Inc. | 2 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| VBI Vaccine (delaware) Inc. | 1 | $19 |
| Verona Pharma, Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,501 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 42 | $49,041 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $46,452 |
| TradjentaLinagliptin | 63 | $46,379 |
| JardianceEmpagliflozin | 57 | $41,445 |
| OzempicSemaglutide | 42 | $38,782 |
| TrulicityDulaglutide | 36 | $35,645 |
| EliquisApixaban | 41 | $33,977 |
| XareltoRivaroxaban | 48 | $32,647 |
| LinzessLinaclotide | 27 | $24,006 |
| FarxigaDapagliflozin Propanediol | 21 | $21,062 |
| JanuviaSitagliptin Phosphate | 17 | $13,535 |
| MovantikNaloxegol Oxalate | 26 | $10,464 |
| Spiriva RespimatTiotropium Bromide | 19 | $9,548 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $7,319 |
| MyrbetriqMirabegron | 14 | $6,229 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance, Spiriva Respimat, Stiolto Respimat | $638 | $102,896151 claims |
| Lilly USA, LLCMounjaro, Trulicity | $869 | $84,68678 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,040 | $56,89882 claims |
| Novo NordiskOzempic | $1,292 | $38,78242 claims |
| PfizerEliquis | $466 | $33,97741 claims |
| Johnson & JohnsonXarelto | $451 | $32,64748 claims |
| AbbVieLinzess | $1,460 | $24,00627 claims |
| AstraZenecaFarxiga | $1,373 | $21,06221 claims |
| MerckJanuvia, Belsomra | $40 | $18,10928 claims |
| Redhill Biopharma Inc.Movantik | $48 | $10,46426 claims |
| Astellas Pharma US IncMyrbetriq | $146 | $6,22914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Farmington
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
- Patricia HabdasPittsburgh$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.